Mavrilimumab

DB12534InvestigationalProtein Based Therapies

Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.

Mechanism: Pharmacologically active on Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Curator reviewed
Code names: CAM-3001 · KPL-301

Resolves to

Compound

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mavrilimumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.